We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SOPs Should Detail DMC Use to Comply With FDA Guidance
SOPs Should Detail DMC Use to Comply With FDA Guidance
September 24, 2009
While the FDA guidance is nonbinding, companies should follow it to avoid getting warning letters, having applications for investigational new drugs or investigational device exemptions rejected, facing tort liability and increasing the risk of trial suspension or termination.